Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy—California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial

Abstract only

Saved in:

Bibliographic Details
Published in	Journal of clinical oncology Vol. 26; no. 15_suppl; p. 16058
Main Authors	Cheung, E. M., Quinn, D. I., Tsao-Wei, D. D., Groshen, S. G., Aparicio, A. M., Twardowski, P., Chatta, G. S., Lara, P. N., Gandara, D. R.
Format	Journal Article
Language	English
Published	20.05.2008
Online Access	Get full text

Loading…